References
- He B, Lin X, Tian F, et al. MiR-133a-3p inhibits oral squamous cell carcinoma (OSCC) proliferation and invasion by suppressing COL1A1. J Cell Biochem. 2018;119(1):338–346.
- Sinevici N, O’Sullivan J. Oral cancer: deregulated molecular events and their use as biomarkers. Oral Oncol. 2016;61:12–18.
- Morais MO, Elias MR, Leles CR, et al. The effect of preventive oral care on treatment outcomes of a cohort of oral cancer patients. Support Care Cancer. 2016;24(4):1663–1670.
- Alzahrani R, Alrehaili AA. Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma. J Cancer Prev. 2020;25(1):21–26.
- Mücke T, Mitchell DA, Ritschl LM, et al. Influence of tumor volume on survival in patients with oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2015;141(6):1007–1011.
- Mücke T, Wolff K-D, Wagenpfeil S, et al. Immediate microsurgical reconstruction after tumor ablation predicts survival among patients with head and neck carcinoma. Ann Surg Oncol. 2010;17(1):287–295.
- Chen L, Zhu Q, Lu L, et al. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1. Bioengineered. 2020;11(1):91–102.
- Baltimore D, Boldin MP, O’connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9(8):839.
- Pang H, Xu X, Dai L, et al. MicroRNA‑195 is associated with regulating the pathophysiologic process of human laryngeal squamous cell carcinoma. Mol Med Rep. 2018;17(4):5283–5291.
- Si W, Shen J, Zheng H, et al. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11(1):25.
- Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell. 2013;153(3):516–519.
- Chang YC, Jan CI, Peng CY, et al. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas. Oncotarget. 2015;6(27):24002–24016.
- Deng L, Liu H. MicroRNA-506 suppresses growth and metastasis of oral squamous cell carcinoma via targeting GATA6. Int J Clin Exp Med. 2015;8(2):1862–1870.
- Lin X, Duan X, Liang YY, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 2006;125(5):915–928.
- Sun W, Yu Y, Dotti G, et al. PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation. Cell Signal. 2009;21(1):95–102.
- Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Res. 2012;2012:659649.
- Shohat M, Ben-Meir D, Lavi S. Protein phosphatase magnesium dependent 1A (PPM1A) plays a role in the differentiation and survival processes of nerve cells. PloS One. 2012;7(2):e32438.
- Lammers T, Lavi S. Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling. Crit Rev Biochem Mol Biol. 2007;42(6):437–461.
- Zhang B, Zhou Z, Lin H, et al. Protein phosphatase 1A (PPM1A) is involved in human cytotrophoblast cell invasion and migration. Histochem Cell Biol. 2009;132(2):169–179.
- Shao Y, Qu Y, Dang S, et al. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int. 2013;13(1):51.
- Hou Y, Li L, Ju Y, et al. MiR-101-3p Regulates the Viability of Lung Squamous Carcinoma Cells via Targeting EZH2. J Cell Biochem. 2017;118(10):3142–3149.
- Zhou J, Qie S, Fang H, et al. MiR-487a-3p suppresses the malignant development of pancreatic cancer by targeting SMAD7. Exp Mol Pathol. 2020;116:104489.
- Wang M, Yu W, Gao J, et al. MicroRNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1. J Cell Physiol. 2020;235(2):1588–1600.
- Zurawek M, Dzikiewicz-Krawczyk A, Izykowska K, et al. miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3. Diabetes Res Clin Pract. 2018;142:146–153.
- Gao J, Zhang L, Liu Z, et al. Effect of miR-135b inhibitor on biological characteristics of osteosarcoma cells through up-regulating PPM1A. Int J Clin Exp Pathol. 2019;12(3):689–699.